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Streptococcus pneumoniae is a leading cause of meningitis,
sepsis, community-acquired pneumonia and acute otitis
media in both adults and children [1,2]. The availability of
penicillin and other antibiotics since the 1940s has led to
reduced morbidity and mortality associated with pneumococ-
cal infections. However, the widespread availability and over-
use of antibiotics has led to global pneumococcal resistance.
Given the public health implications of antibiotic overuse,
which global strategies are most likely to reduce the dangers
associated with (often multidrug-resistant) S. pneumoniae?
An important strategy in reducing antibiotic resistance has
been the development of the seven-valent pneumococcal
conjugate vaccine (PCV7). PCV7 contains serotypes 4, 6B,
9V, 14, 18C, 19F and 23F [3], and the vaccine has been
introduced into national childhood immunization pro-
grammes in many countries worldwide. PCV7 has been
remarkably effective in reducing pneumococcal disease
among vaccinated children and non-vaccinated children and
adults, owing to herd immunity [3,4]. Stephens et al., report-
ing on macrolide resistance in the USA, suggested that
PCV7 may be a powerful strategy for reducing antibiotic
resistance in a community [5]. Kyaw et al. observed that the
rate of antibiotic-resistant invasive pneumococcal infections
decreased in young children and older persons aged
‡65 years after the introduction of PCV7 in the USA in
2000 [6]. Of note, these authors draw our attention to the
fact that there was an increase in the frequency of infections
caused by serotypes not included in the vaccine, particularly
serotype 19A. Pneumococcal resistance may be partially
addressed by vaccine introduction, but reducing antibiotic
abuse/overuse is an important factor in controlling resis-
tance. Replacement disease due to non-vaccine serotypes is
an emerging concern (Picazo J, Contreras JR, Mendez C
et al. Poster presented at 26th Annual Meeting of the Euro-
pean Society for Paediatric Infectious Diseases, Graz, Austria,
13–17 May 2008; Sanz JC, Ramos B, Ochoa D et al. 6th
International Symposium on Pneumococci and Pneumococcal
Diseases, Reykjavik, Iceland, 8–12 June 2008. Abstract P1-011).
These issues were the focus of a symposium entitled ‘The
Management of Antibiotic-resistant Streptococcus pneumoniae
Infections and the Use of Pneumococcal Conjugate Vaccine’,
which was convened at the European Congress of Clinical
Microbiology and Infectious Diseases on 20 April 2008, in
Barcelona, Spain. The symposium was sponsored by Wyeth
Pharmaceuticals, Inc.
In the opening session of the symposium, J.J. Picazo
(Madrid, Spain) spoke about the public health implications
of pneumococcal infections and the WHO position paper
stressing the value of a pneumococcal vaccine in preventing
pneumococcal resistance [7]. He described the European
Antimicrobial Resistance Surveillance System, which docu-
ments temporal variations in antimicrobial resistance as a
way to assess the effectiveness of prevention programmes.
He reviewed epidemiological studies in Spain that have
tracked the antimicrobial sensitivity patterns of multiresistant
bacteria, as well as changes in pneumococcal serotype distri-
bution, clinical syndromes and underlying disease since the
introduction of PCV7 [8,9]. Although antibiotic resistance
throughout the world is increasing, these studies indicate
that, in Spain, overall antibiotic use and resistance have
decreased in conjunction with vaccine use.
In the next presentation, I emphasized that antibacterial
resistance in pneumococci is increasing worldwide, primarily
to b-lactams and macrolides. In European countries such as
France and Spain, up to 36% of pneumococci display multidrug
(defined as resistance to three or more antibiotics) resistance
to macrolides and penicillin [10]. A number of mechanisms
conferring macrolide resistance have been described. These
include resistance mediated through the erm(B) gene, which
results in a macrolide–lincosamide–streptogramin B resis-
tance, or through the mef(A) gene, which encodes an antibi-
otic efflux pump [11]. I also discussed the ‘replacement
phenomenon’, which has been associated with certain pneu-
mococcal serotypes or certain clones. This phenomenon may
be responsible for the fact that, since the introduction of
PCV7, the rate of invasive pneumococcal disease among vacci-
nated children aged <5 years has significantly decreased in
many countries and, in some countries where PCV7 is widely
used, an increase (relative and absolute) of non-PCV7 vaccine
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serotypes has been observed. I discussed the roles of adapta-
tion and competence in the evolution of S. pneumoniae and
reviewed data from the Prospective Resistant Organism
Tracking and Epidemiology for Ketolide Telithromycin
(PROTEKT) study demonstrating the extreme variability of
pneumococcal drug resistance from country to country [12].
Next, H. Goossens (Antwerp, Belgium) outlined the role of
antibiotic overuse in causing drug resistance in streptococci,
and factors such as dose and duration of antibiotics and cross-
selection that also contribute to resistance. In a global over-
view of antibiotic prescribing patterns, he discussed results
from the European Surveillance of Antimicrobial Consumption
as compared with antibiotic usage in the USA. The highest
consumption of antibiotics was observed in southern Euro-
pean countries such as Greece, France and Italy; northern
European countries reported comparatively lower antibiotic
use, with The Netherlands reporting the least. Of note, outpa-
tient antibiotic use in the USA was similar to that in southern
Europe [13]. Marked variations across countries were
observed in the use of short-acting, intermediate-acting and
long-acting macrolides. Extreme seasonal variation was noted
among the European countries, which suggests inappropriate
use for winter conditions such as viral upper respiratory tract
infections (‘cold’), influenza and bronchitis [14]. H. Goossens
also described the relationship between antibiotic use and
resistance, citing evidence that erythromycin-resistant strains
correlate with the use of azithromycin, as well as describing
a positive correlation between the use of penicillin or
erythromycin and the development of penicillin-resistant
S. pneumoniae [15].
Next, R. Dagan (Beer-Sheva, Israel) explained that vaccines
reduce pneumococcal resistance in both vaccinated indivi-
duals, and their contacts, by reducing the transmission of
antibiotic-resistant serotypes and by decreasing the use of
antibiotics. He then reported results from the Active
Bacterial Core Surveillance Program (CDC), which analysed
the effect of PCV7 on invasive disease caused by penicillin-
resistant strains. In children younger than 2 years of age who
received the vaccine, an 81% decrease in the rate of invasive
disease caused by penicillin-resistant pneumococci was
observed. An increase in infections caused by serotypes not
included in PCV7 was also noted [6]. Other studies of Israeli
and US children have demonstrated a significant reduction in
antibiotic use for respiratory problems and otitis media fol-
lowing administration of PCV7 [16,17]. He also highlighted
the increasing threat from serotype 19A, which is the most
prevalent and clinically important serotype. Serotype 19A is
highly antibiotic-resistant, and serotype 19F, included in
PCV7, does not confer cross-protection. Although the vac-
cine may facilitate the spread of serotype 19A by reducing
competition, the data strongly suggest that frequent antibi-
otic use in the community is a major contributor to the
increase in serotype 19A prevalence [18,19].
In the final presentation of the symposium, R. Cohen
(Crete´il, France) emphasized the use of PCV to reduce anti-
biotic resistance. He described a US study that compared
prescriptions for acute otitis media from 1997 (pre-PCV7)
to 2004 (post-PCV7), and that showed a 41.9% reduction in
antibiotic prescriptions following implementation of the
PCV7 immunization programme [20]. He reviewed several
other European epidemiological studies that showed that
the administration of PCV7 and nine-valent PCV (PCV9)
significantly decreased antibiotic prescriptions in children.
In France, for example, the rates of highly penicillin-resistant
strains decreased from 15.4% to 6.7% [21]. R. Cohen also
highlighted several studies that demonstrated that the
implementation of PCV7 has significantly reduced the
carriage of vaccine-serotype pneumococci and increased
carriage of non-vaccine serotypes.
The public health ramifications of pneumococcal resistance
make apparent the need for effective prevention pro-
grammes that will create strong links between those who
propose public health policy and those involved in research
and clinical practice. Prudent use of antibiotics is the key to
decreasing, or even reversing, the spread of resistance.
Another equally important factor in decreasing antibiotic use
is ensuring that individuals at greatest risk of bacterial dis-
eases—including children, the elderly, and those with chronic
illnesses—are vaccinated against those diseases.
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